1, Fosun Pharma takes pharmaceutical business as its core and insists on innovative research and development. Through independent research and development, cooperative development, authorization and deep incubation, Fosun Pharma has built and formed small molecule innovative drugs, antibody drugs and drugs around key diseases such as tumor, immune regulation and four highs (hypertension, hyperlipidemia, hyperglycemia and hyperuricemia). ), complications and central nervous system cell therapy technology platform, actively explore cutting-edge technical fields such as targeted protein degradation, RNA, oncolytic virus and gene therapy, and improve innovation ability. Up to now, there are 49 major institutions with total positions of11340,000 shares, accounting for 56.38% of circulating A shares.
2. The recent average cost is 55.68 yuan, and the stock price runs above the cost. The upward trend of the bull market is slowing down, and it can be appropriately thrown high and sucked low. The company operates well, and most institutions believe that the long-term investment value of the stock is high. On the one hand, the transaction volume inside the movie line is quite large. With the stock price diving, these funds are still in a locked state, which has certain pressure on the market outlook; On the other hand, we noticed that the transaction volume of the inconspicuous shadow line on that day was also obviously enlarged, which indicated that while diving triggered panic selling, there were still funds to take over.
3. Considering the obvious large-scale process near the low point, it can be seen that the bargain-hunting fund is expanding its fundraising scale. In this way, the possibility of these two negative lines washing dishes recently has greatly increased. Since 56.44-6 1.32 is a transaction-intensive area and the hardest hit area, there will naturally be a lot of liquidation spillovers since the stock price has risen, thus forming a strong pressure on the stock price. Fosun Pharma has a two-year bottoming process between 24 and 30 yuan, which fundamentally determines that the future market will not stop at 79.07 yuan. However, a healthy bull market usually goes through a slow, rapid and urgent gradual process, but Fosun Pharma rises directly from the ground. The rapid rise will lead to a large number of follow-up orders, creating a good opportunity for institutions to throw high.
4. Fosun Pharma continues to fluctuate sideways at this stage, showing a convergent triangle. At present, it is difficult to judge the nature of this triangle, whether it is a bottoming process or a downward relay. However, it is obvious that the volume of transactions has obviously expanded, which leads to the region becoming another centralized shareholding region, which indicates that when the stock price returns to the region, there will be a large number of liquidation spillovers, which will put pressure on the stock price. The future prospect of Fosun Pharma's stock can be said to be very bright. For value investors, it is not too late to start to lay out the shares of Fosun Pharma, because its COVID-19 vaccine has just started to go on the market slowly, and the company's profits will continue to grow, and its share price will rise slowly.